New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus

The purpose of this study is to test the safety of triptorelin when used for the protection
of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for
systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on
you. The study will be done with female patients who have been diagnosed with Systemic
Lupus Erythematosus, are younger than 21 years of age, and require intravenous
cyclophosphamide to control the disease. Each patient will be in the study for
approximately 23 months, until 4 months after your intravenous cyclophosphamide treatment
has been completed.

This study is being conducted at 7 sites across the United States (New York, Chicago,
Milwaukee, Columbus, Seattle, Los Angeles, Cincinnati). A total of 50 patients will
participate in this study.

Each patient will be randomized (assigned) to one of 5 groups. Randomization means that you
are put into a group completely by chance. It is like flipping a coin. Neither the patient
nor the study staff knows what group the patient is in. The patient has a 20% chance of
being placed in any group.